<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216005</url>
  </required_header>
  <id_info>
    <org_study_id>CLN 003</org_study_id>
    <nct_id>NCT03216005</nct_id>
  </id_info>
  <brief_title>Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System</brief_title>
  <acronym>INFINITE-OUS</acronym>
  <official_title>Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intervene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intervene, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the BlueLeaf System for the restoration of venous
      competence for the treatment of symptomatic chronic venous insufficiency (CVI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, non-randomized, multicenter pre-market feasibility study to evaluate subjects
      treated with the BlueLeaf System for the treatment of symptomatic CVI of the lower extremity.
      The BlueLeaf System is designed to form autogenous tissue leaflets from vein walls in the
      femoral and popliteal veins without the use of a permanent vascular implant for the treatment
      of CVI. Subjects meeting eligibility criteria will be enrolled and may be followed through 5
      years post treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective, non-randomized, multicenter pre-market feasibility study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent decrease in reflux time (RT) in the primary treated vein segment from pre-procedure baseline to the 30-day follow-up imaging study</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from target vessel deep venous thrombosis (DVT) at the 30-day follow-up imaging study.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>BlueLeaf System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BlueLeaf System</intervention_name>
    <description>The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.</description>
    <arm_group_label>BlueLeaf System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic CVI subjects, Clinical Etiological Anatomical Pathophysiological (CEAP)
             grade 3 to 6;

          -  Failed compression therapy of at least 6 months' duration;

          -  Deep system venous reflux characterized by &gt;1 second reflux time;

          -  Presence of at least one target site within the target vessel.

        Exclusion Criteria:

          -  Untreated significant superficial venous incompetence which, in the opinion of the
             Investigator, may be the primary source of existing symptoms;

          -  Deep venous intervention in the target limb or outflow vessels within 6 months of
             consent;

          -  Significant peripheral arterial disease with an ankle-brachial index of &lt;0.50 or with
             incompressible vessels;

          -  Acute deep venous thrombosis (DVT) within 3 months of consent;

          -  History of stroke within the last 6 months;

          -  Flow-limiting venous outflow obstruction central to the intended target sites;

          -  Insufficient inflow through the treatment vein upon manual augmentation;

          -  Chronic, diffuse, post-thrombotic femoropopliteal vein disease that, in the
             Investigator's opinion, would preclude venous valve formation or would inhibit flow
             through the treatment sites;

          -  Chronic renal insufficiency with creatinine level of â‰¥2mg/dL;

          -  Hemoglobin level &lt;9.0 mg/dL;

          -  Platelet count &lt;50,000 or &gt;1,000,000 per mm3;

          -  Total white blood cell count &lt;3,000/mm3;

          -  Pregnant or lactating female; positive pregnancy test, women of childbearing potential
             must be tested;

          -  Non-ambulatory patients;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fletcher Wilson</last_name>
    <role>Study Director</role>
    <affiliation>Intervene, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandi Johnson</last_name>
    <phone>650-351-6725</phone>
    <email>brandi@intervene-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Prince Alfred</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Turner</last_name>
      <email>Lisa.Turner@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>David Robinson, FRACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Katae</last_name>
      <email>dkatae@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Andrew Hill, FRACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Holden, FRANZCR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials New Zealand Ltd</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Bisley</last_name>
      <email>eileen@clinicaltrialsnz.com</email>
    </contact>
    <investigator>
      <last_name>Thodur Vasudevan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

